Table 1.
Clinical characteristics of the study population (n = 115)
| Patient characteristics | |
|---|---|
| Age (years) | 59 ± 12 |
| Male gender | 53 |
| BMI (kg/m2) | 25.9 ± 4.6 |
| Heart rate (beats per minute) | 74 ± 12 |
| Baseline CV risk factors | |
| HF/cardiomyopathy | 20.9 |
| MI or PCI or CABG | 13.9 |
| Hypertension | 20.9 |
| DM | 13.0 |
| Hyperlipidemia | 15.6 |
| Obesity (BMI > 30 kg/m2) | 22.2 |
| Smoking | 36.5 |
| Main oncological diagnosis | |
| Gastrointestinal | 27.6 |
| Genitourinary | 15.2 |
| Breast | 14.3 |
| Gynecological | 14.3 |
| Head and neck | 9.5 |
| Thoracic | 9.5 |
| Sarcoma | 5.7 |
| Central nervous system | 1.9 |
| Othera | 1.9 |
| Potentially cardiotoxic chemotherapy | |
| Anthracycline chemotherapy | 15.7 |
| HER-2 targeted therapies | 10.4 |
| VEGF inhibitors | 17.4 |
| RAF and MEK inhibitors | 0.8 |
| Chest radiotherapy | 9.6 |
Values are mean ± SD or percentage (%) of patients unless otherwise indicated.
BMI, body mass index; CABG, coronary artery bypass graft; CV, cardiovascular; DM, diabetes mellitus; HER-2, human epidermal receptor 2; HF, heart failure; LVEF, left ventricular ejection fraction; MEK, mitogen-activated extracellular signal-regulated kinase; MI, myocardial infarction; PCI, percutaneous coronary intervention; RAF, rapidly accelerated fibrosarcoma; VEGF, vascular endothelial growth factor.
aNeuroendocrine tumour, skin cancer.